Clinical data | |
---|---|
Trade names | Epidaza, Hiyasta |
Other names | Chidamide, HBI-8000 |
ATC code |
|
Identifiers | |
| |
CAS Number | |
PubChem CID | |
DrugBank | |
ChemSpider | |
UNII | |
KEGG | |
ChEMBL | |
CompTox Dashboard ( EPA) | |
Chemical and physical data | |
Formula | C22H19FN4O2 |
Molar mass | 390.418 g·mol−1 |
3D model ( JSmol) | |
| |
|
Tucidinostat ( INN, also known as chidamide and sold under the brand names Epidaza and Hiyasta) is a histone deacetylase inhibitor (HDI) developed in China. [1] It was also known as HBI-8000. [2] It is a benzamide HDI and inhibits Class I HDAC1, HDAC2, HDAC3, as well as Class IIb HDAC10. [3]
Tucidinostat is approved by the Chinese FDA for relapsed or refractory peripheral T-cell lymphoma (PTCL) and has orphan drug status in Japan. [2][ better source needed] In Japan, it was approved for relapsed or refractory adult T-cell leukemia-lymphoma (ATLL) treatment in June 2021. [4]
Tucidinostat is being researched as a treatment for pancreatic cancer. [5] [6] [7] However, it is not US FDA approved for the treatment of pancreatic cancer.
Clinical data | |
---|---|
Trade names | Epidaza, Hiyasta |
Other names | Chidamide, HBI-8000 |
ATC code |
|
Identifiers | |
| |
CAS Number | |
PubChem CID | |
DrugBank | |
ChemSpider | |
UNII | |
KEGG | |
ChEMBL | |
CompTox Dashboard ( EPA) | |
Chemical and physical data | |
Formula | C22H19FN4O2 |
Molar mass | 390.418 g·mol−1 |
3D model ( JSmol) | |
| |
|
Tucidinostat ( INN, also known as chidamide and sold under the brand names Epidaza and Hiyasta) is a histone deacetylase inhibitor (HDI) developed in China. [1] It was also known as HBI-8000. [2] It is a benzamide HDI and inhibits Class I HDAC1, HDAC2, HDAC3, as well as Class IIb HDAC10. [3]
Tucidinostat is approved by the Chinese FDA for relapsed or refractory peripheral T-cell lymphoma (PTCL) and has orphan drug status in Japan. [2][ better source needed] In Japan, it was approved for relapsed or refractory adult T-cell leukemia-lymphoma (ATLL) treatment in June 2021. [4]
Tucidinostat is being researched as a treatment for pancreatic cancer. [5] [6] [7] However, it is not US FDA approved for the treatment of pancreatic cancer.